Do analysts rate OBSV or BGM?

Given ObsEva's higher probable upside, research analysts clearly believe ObsEva is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, OBSV or BGM?

BGM Group has higher revenue and earnings than ObsEva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A BGM Group $37.92M 0.75 -$19.94M N/A N/A

Is OBSV or BGM more profitable?

BGM Group's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% BGM Group N/A N/A N/A

Do analysts prefer ACTU or OBSV?

Actuate Therapeutics currently has a consensus target price of $13.67, indicating a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ACTU or OBSV?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is ACTU or OBSV more profitable?

ObsEva's return on equity of -416.36% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% ObsEva N/A -416.36% -92.01%

Do analysts rate OPTH or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is OPTH or OBSV more profitable?

Optimi Health's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Optimi Health N/A N/A N/A ObsEva N/A -416.36% -92.01%

Do analysts recommend MIRA or OBSV?

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, MIRA or OBSV?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is MIRA or OBSV more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% ObsEva N/A -416.36% -92.01%

ObsEva (OBSV) Competitors

Compare

OBSV vs. BGM, PYRGF, ACTU, OPTH, and MIRA

Should you buy ObsEva stock or one of its competitors? ObsEva's main competitors and comparable companies include BGM Group (BGM), PyroGenesis Canada (PYRGF), Actuate Therapeutics (ACTU), Optimi Health (OPTH), and MIRA Pharmaceuticals (MIRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ObsEva compare to BGM Group?

ObsEva (NASDAQ:OBSV) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

BGM Group's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
BGM Group	N/A	N/A	N/A

17.5% of ObsEva shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BGM Group has higher revenue and earnings than ObsEva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
BGM Group	$37.92M	0.75	-$19.94M	N/A	N/A

In the previous week, BGM Group had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for BGM Group and 0 mentions for ObsEva. BGM Group's average media sentiment score of 1.89 beat ObsEva's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
BGM Group	Very Positive

Given ObsEva's higher probable upside, research analysts clearly believe ObsEva is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Summary

BGM Group beats ObsEva on 9 of the 11 factors compared between the two stocks.

How does ObsEva compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

ObsEva has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
ObsEva	N/A	-416.36%	-92.01%

PyroGenesis Canada has higher revenue and earnings than ObsEva. PyroGenesis Canada is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.65	-$21.12M	-$0.04	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

In the previous week, PyroGenesis Canada's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
ObsEva	Neutral

PyroGenesis Canada has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

PyroGenesis Canada beats ObsEva on 6 of the 10 factors compared between the two stocks.

How does ObsEva compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Actuate Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Actuate Therapeutics currently has a consensus target price of $13.67, indicating a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

17.5% of ObsEva shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

ObsEva's return on equity of -416.36% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
ObsEva	N/A	-416.36%	-92.01%

In the previous week, Actuate Therapeutics had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for Actuate Therapeutics and 0 mentions for ObsEva. Actuate Therapeutics' average media sentiment score of 0.96 beat ObsEva's score of 0.00 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
ObsEva	Neutral

Summary

Actuate Therapeutics beats ObsEva on 8 of the 13 factors compared between the two stocks.

How does ObsEva compare to Optimi Health?

Optimi Health (NASDAQ:OPTH) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Optimi Health's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Optimi Health	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

Optimi Health has higher revenue and earnings than ObsEva. Optimi Health is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Optimi Health	$290K	94.64	-$1.12M	-$0.36	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

In the previous week, Optimi Health had 7 more articles in the media than ObsEva. MarketBeat recorded 7 mentions for Optimi Health and 0 mentions for ObsEva. Optimi Health's average media sentiment score of 1.43 beat ObsEva's score of 0.00 indicating that Optimi Health is being referred to more favorably in the media.

Company	Overall Sentiment
Optimi Health	Positive
ObsEva	Neutral

17.5% of ObsEva shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Optimi Health beats ObsEva on 8 of the 12 factors compared between the two stocks.

How does ObsEva compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

MIRA Pharmaceuticals has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Given ObsEva's higher possible upside, analysts plainly believe ObsEva is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

MIRA Pharmaceuticals' return on equity of -106.95% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
ObsEva	N/A	-416.36%	-92.01%

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for ObsEva. MIRA Pharmaceuticals' average media sentiment score of 1.47 beat ObsEva's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
ObsEva	Neutral

Summary

MIRA Pharmaceuticals beats ObsEva on 9 of the 13 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.94M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	0.00	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	N/A	11.60	12.91	6.24
Net Income	-$58.38M	$2.77B	$3.45B	$347.60M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
BGM BGM Group	0.9305 of 5 stars	$0.31 +3.3%	N/A	-96.0%	$29.85M	$37.92M	N/A	298	Positive News
PYRGF PyroGenesis Canada	N/A	$0.13 flat	N/A	-44.8%	$29.57M	$9.14M	N/A	90
ACTU Actuate Therapeutics	3.6516 of 5 stars	$1.21 +7.1%	$13.67 +1,029.5%	-88.6%	$28.95M	N/A	N/A	10	News Coverage Earnings Report Short Interest Decrease
OPTH Optimi Health	1.8004 of 5 stars	$5.03 -0.4%	N/A	N/A	$28.80M	$231.86K	N/A	N/A	News Coverage Positive News Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. BGM, PYRGF, ACTU, OPTH, and MIRA

How does ObsEva compare to BGM Group?

Summary

How does ObsEva compare to PyroGenesis Canada?

Summary

How does ObsEva compare to Actuate Therapeutics?

Summary

How does ObsEva compare to Optimi Health?

Summary

How does ObsEva compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. BGM, PYRGF, ACTU, OPTH, and MIRA

How does ObsEva compare to BGM Group?

Is OBSV or BGM more profitable?

Do insiders & institutionals believe in OBSV or BGM?

Which has preferable earnings & valuation, OBSV or BGM?

Does the media favor OBSV or BGM?

Do analysts rate OBSV or BGM?

Which has more risk & volatility, OBSV or BGM?

Summary

How does ObsEva compare to PyroGenesis Canada?

Is PYRGF or OBSV more profitable?

Which has better earnings & valuation, PYRGF or OBSV?

Does the media favor PYRGF or OBSV?

Which has more volatility and risk, PYRGF or OBSV?

Do institutionals and insiders believe in PYRGF or OBSV?

Summary

How does ObsEva compare to Actuate Therapeutics?

Which has more volatility & risk, ACTU or OBSV?

Do analysts prefer ACTU or OBSV?

Do institutionals & insiders believe in ACTU or OBSV?

Which has higher valuation & earnings, ACTU or OBSV?

Is ACTU or OBSV more profitable?

Does the media prefer ACTU or OBSV?

Summary

How does ObsEva compare to Optimi Health?

Do analysts rate OPTH or OBSV?

Is OPTH or OBSV more profitable?

Which has higher valuation & earnings, OPTH or OBSV?

Does the media refer more to OPTH or OBSV?

Do insiders & institutionals have more ownership in OPTH or OBSV?

Summary

How does ObsEva compare to MIRA Pharmaceuticals?

Which has preferable earnings and valuation, MIRA or OBSV?

Which has more volatility & risk, MIRA or OBSV?

Do analysts recommend MIRA or OBSV?

Is MIRA or OBSV more profitable?

Do insiders and institutionals hold more shares of MIRA or OBSV?

Does the media refer more to MIRA or OBSV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools